170115-98-7

Basic information

• Product Name: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE
• Synonyms: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE;[2-[[(1R,2R)-1-hydroxy-1-phenylpropan-2-yl]-methylamino]-2-oxoethyl]azanium
• CAS NO: 170115-98-7
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.28
• Product Categories: pharmacetical
• Mol File: 170115-98-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 397.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.140±0.06 g/cm3(Predicted)
• PKA: 13.71±0.20(Predicted)
• CAS DataBase Reference: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE(170115-98-7)
• EPA Substance Registry System: (R,R)-(-)-PSEUDOEPHEDRINE GLYCINAMIDE(170115-98-7)

Safety Data

• Hazardous Substances Data: 170115-98-7(Hazardous Substances Data)

Usage

Uses

(R,R)-(-)-Pseudoephedrine Glycinamide is a building block used as a reactant in the synthesis of macrocyclic trypanosomal cysteine protease inhibitors and in the synthesis of α-amino acids.

Upstream product

• 4530-20-5 BOC-glycine 
• 321-97-1 (1R,2R)-pseudoephedrine 
• 616-34-2 methoxycarbonylmethylamine 
• 3282-30-2 pivaloyl chloride 
• 5680-79-5 glycine ethyl ester hydrochloride 
• 170115-96-5 2-amino-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylacetamide 

Downstream Products

• 173913-77-4 <-2S>-N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methyl 2-amino-3-(2-(5-benzenesulfonyloxy)pyridyl)propionamide 
• 225938-47-6 <1R(S),2R>-N-(2-hydroxy-1-methyl-2-phenethyl)-2-amino-N-methyl-4-pentenamide 
• 652990-46-0 (2S)-2-amino-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-4-methylpent-4-enamide 
• 634585-80-1 (S)-2-Amino-11-methoxy-undecanoic acid ((1R,2R)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide 
• 851785-13-2 C₂₀H₂₆N₂O₂S 
• 880347-42-2 2-amino-3-(3-bromo-phenyl)-N-((2R)-hydroxy-(1R)-methyl-2-phenyl-ethyl)-N-methyl-propionamide 
• 176754-77-1 Carbonic acid 5-{(S)-2-amino-2-[((1R,2R)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-carbamoyl]-ethyl}-4-(tert-butoxycarbonylamino-methyl)-2-methyl-pyridin-3-yl ester tert-butyl ester 
• 90600-20-7 (2S)-2-[(tert-butoxycarbonyl)amino]pent-4-enoic acid 
• 1319191-90-6 (S)-2-amino-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methylhept-6-enamide 
• 1268382-00-8 C₁₈H₂₄N₂O₄S₂ 
• 1095239-02-3 (R,R)-pseudoephedrine (S)-2-amino-5-hexenoic amide 
• 225938-51-2 2-amino-3-[5-(tert-butyl-dimethyl-silanyloxy)-2,4-dimethoxy-3-methyl-phenyl]-N-(2-hydroxy-1-methyl-2-phenyl-ethyl)-N-methyl-propionamide 

Relevant articles and documents

NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF

The present invention relates to oligomer compounds, including dimers and trimers, formed by a disulfide, sulfinyl thio, olefin or hydrocarbon bond, or a hydrazone exchange bond between two or more monomers. Methods of making the monomers and the oligomers is also disclosed. Use of the compounds for inhibiting the activity of target RNA molecules, particularly those having a secondary structure that include a stem or stem-loop formation. Dimer compounds capable of inhibiting the activity of an HIV-1 RNA frameshifting stem-loop and a (CUG)n expanded repeat stem- loop are disclosed, as are methods of treating diseases associated with these target RNA molecules.

Aspartyl protease inhibitors

The present invention provides compounds having the formula: wherein R1, R′, R2, R3, R3′, R4, X1, X2 and X3 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting proteases, more specifically aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer's Disease). The present invention also provides methods for preparing compounds of the invention.

ASPARTYL PROTEASE INHIBITORS

The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.